Oncology leaders weigh how to scale trustworthy AI platforms, align governance, and integrate care-research workflows for ...
The FDA has approved daraxonrasib for patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). 1.
The American Society of Clinical Oncology (ASCO) has released its inaugural guideline on the systemic treatment of recurrent ...
An exploratory analysis from the SECOMBIT trial showed differences in outcomes based on thymidine kinase activity in ...
The recent FDA approval of iberdomide (Zenbexus) represents more than the approval of a single new drug for ...
AI-powered trial screening helps community oncology practices identify eligible patients locally, widening access beyond ...
Zanidatamab plus tislelizumab and chemotherapy reduced mortality risk by 28% versus trastuzumab plus chemotherapy, delivering ...
The first patient has been dosed in MODeFIRe-1 (NCT07745361), a phase 2 study evaluating MRT-2359 in combination with ...
Priority review reflects AZUR-1 meeting its primary end point of meaningful, sustained 12-month cCR in dMMR/MSI-H stage ...
Sustained MRD negativity at 12 months was higher with D-VRd, with similar advantages at 24 and 36 months and a lower rate of ...
Primary endpoint results showed no SSE-FS benefit with radium-223 addition (HR 1.46; 1-sided P=.12), while OS, PFS, and ORR ...
Laila Alkhouli, MD, of Cleveland Children's Clinic outlines critical findings from research evaluating how care teams across ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results